NasdaqGS - Nasdaq Real Time Price USD

Cumberland Pharmaceuticals Inc. (CPIX)

1.6500 +0.0800 (+5.10%)
At close: April 18 at 4:00 PM EDT
1.6500 0.00 (0.00%)
After hours: April 18 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
39,552.5070
39,552.5070
42,010.9490
35,985.0430
37,441.1340
Cost of Revenue
6,066.6110
6,066.6110
9,118.5210
8,811.2480
8,653.0200
Gross Profit
33,485.8960
33,485.8960
32,892.4280
27,173.7950
28,788.1140
Operating Expense
43,040.5570
43,040.5570
38,597.3570
34,851.2150
35,169.7090
Operating Income
-9,554.6610
-9,554.6610
-5,704.9290
-7,677.4200
-6,381.5950
Net Non Operating Interest Income Expense
-381.0070
-381.0070
-487.5900
-71.9500
-188.2820
Other Income Expense
3,650.6710
3,650.6710
611.3300
2,187.1400
--
Pretax Income
-6,284.9970
-6,284.9970
-5,581.1890
-5,562.2300
-6,569.8770
Tax Provision
45.7690
45.7690
68.8500
34.8910
55.9020
Net Income Common Stockholders
-6,279.3200
-6,279.3200
-5,570.2410
-3,507.5870
-3,339.4080
Diluted NI Available to Com Stockholders
-6,279.3200
-6,279.3200
-5,570.2410
-3,507.5870
-3,339.4080
Basic EPS
-0.44
-0.44
-0.38
-0.24
-0.22
Diluted EPS
-0.44
-0.44
-0.38
-0.24
-0.22
Basic Average Shares
14,298.7740
14,298.7740
14,563.5920
14,904.8340
15,162.1840
Diluted Average Shares
14,298.7740
14,298.7740
14,563.5920
14,904.8340
15,162.1840
Total Operating Income as Reported
-9,554.6610
-9,554.6610
-5,704.9290
-7,677.4200
-6,381.5950
Total Expenses
49,107.1680
49,107.1680
47,715.8780
43,662.4630
43,822.7290
Net Income from Continuing & Discontinued Operation
-6,279.3200
-6,279.3200
-5,570.2410
-3,507.5870
-3,339.4080
Normalized Income
-6,928.5420
-6,928.5420
-6,053.1917
-5,501.9090
-6,546.2830
Interest Income
286.8540
286.8540
98.4050
26.0810
75.3450
Interest Expense
667.8610
667.8610
585.9950
98.0310
263.6270
Net Interest Income
-381.0070
-381.0070
-487.5900
-71.9500
-188.2820
EBIT
-5,617.1360
-5,617.1360
-4,995.1940
-5,464.1990
-6,306.2500
EBITDA
2,485.5120
2,485.5120
332.9190
-857.8330
-1,557.6850
Reconciled Cost of Revenue
8,398.8050
8,398.8050
8,857.7760
8,576.1820
8,338.5750
Reconciled Depreciation
5,770.4540
5,770.4540
5,328.1130
4,606.3660
4,748.5650
Net Income from Continuing Operation Net Minority Interest
-6,279.3200
-6,279.3200
-5,570.2410
-5,501.9090
-6,546.2830
Total Unusual Items Excluding Goodwill
821.8000
821.8000
611.3300
--
--
Total Unusual Items
821.8000
821.8000
611.3300
--
--
Normalized EBITDA
1,663.7120
1,663.7120
-278.4110
-857.8330
-1,557.6850
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
172.5780
172.5780
128.3793
--
--
12/31/2020 - 8/11/2009
Yahoo Finance Plus Essential access required. Unlock Access

Related Tickers

AVRW Avenir Wellness Solutions, Inc.
0.0400
+25.00%
 
RICH.BA Laboratorios Richmond S.A.C.I.F.
873.00
-3.00%
 
ETON Eton Pharmaceuticals, Inc.
3.0600
-2.55%
 
TKNO Alpha Teknova, Inc.
2.0100
-4.74%
 
ORGO Organogenesis Holdings Inc.
2.8600
+2.51%
 
DCPH Deciphera Pharmaceuticals, Inc.
14.23
-3.33%
 
MEDXF Medexus Pharmaceuticals Inc.
1.1000
-0.90%
 
RGC Regencell Bioscience Holdings Limited
5.22
+19.18%
 
PROC Procaps Group S.A.
2.7000
-2.88%
 
PAHC Phibro Animal Health Corporation
13.04
+1.32%